Colonoscopy is regarded as the gold standard for colorectal cancer screening.
PillCam capsule endoscopy could be an alternative approach for screening large populations.
Dr Devière Schoofs and colleagues from Belgium conducted a pilot evaluation in humans of colon capsule endoscopy compared with colonoscopy.
The researchers evaluated the safety, feasibility, and performance of the 2 techniques.
|Colon capsule endoscopy identified 76% with positive findings|
Patients included in this single-center comparative study presented for screening colonoscopy or had a suspicion of polyps or colorectal cancer.
The capsule was ingested in the morning.
After excretion, the researchers performed colonoscopy.
The team defined significant findings either as polyps more than 6 mm, or 3 or more polyps of any size.
The researchers performed colonoscopy and colon capsule endoscopy review by independent physicians.
The team evaluated 41 patients, of which 26 were women with a mean age of 56 years, and all had complete colonoscopies.
Four patients were excluded due to technical problems and one could not swallow the capsule; thus, 36 patients were considered in the analysis.
In 6 patients, the capsule had not been expelled at 10 hours and was retrieved endoscopically.
Colon capsule endoscopy identified 76% of patients with positive findings, and 77% with significant lesions detected by colonoscopy.
The team noted that colon capsule endoscopy detected 7 lesions not seen at colonoscopy, and 2 tumors were detected by both examinations.
Overall sensitivity of colon capsule endoscopy to detect significant lesions was 77%, and specificity was 70%.
The researchers observed that the positive predictive value was 59%, and the negative predictive value was 84%.
The team found that no adverse events.
Dr Schoofs' team concludes, “Colon capsule endoscopy showed promising accuracy compared with colonoscopy.”
“This new noninvasive technique deserves further evaluation as a potential colorectal cancer screening tool.”